Olatorepatide Shows Promising Weight Loss Results at EASD 2026 Conference

Promising Results from Olatorepatide in Weight Management

The European Association for the Study of Diabetes (EASD) held its annual conference from September 28 to October 2, 2026, in Milan, Italy. Among the exciting presentations was a late-breaking oral report on Olatorepatide, a dual-selective agonist of GLP-1/GIP developed by Hansoh Pharma. The results from a phase III trial, known as LIGHTEN, showcased the significant weight loss achieved by participants following administration of Olatorepatide.

At the 48-week mark, participants receiving a dosage of 15 mg of Olatorepatide experienced an impressive average weight loss of 19.3%. Notably, this continued reduction did not plateau, suggesting that prolonged treatment could yield even greater benefits. Additionally, the average waist circumference reduction for this group was recorded at 16.0 cm, emphasizing the compound's potential for impactful body composition changes.

The LIGHTEN study featured a total of 604 adult participants from China, all either overweight or obese. Those included exhibited a Body Mass Index (BMI) of 28 kg/m² or higher, or a BMI between 24 to 28 kg/m² in concurrence with at least one weight-related comorbidity. Enrolled individuals were randomized to receive weekly subcutaneous injections of Olatorepatide at doses of 5 mg, 10 mg, or 15 mg, or a placebo. The study's primary end points were to measure the percentage weight change from baseline over the 48 weeks and the proportion of participants achieving at least a 5% body weight reduction.

The efficacy outcomes were noteworthy. Participants administered the lower doses of Olatorepatide (5 mg and 10 mg) achieved respective weight losses of 12.5% and 17.5%, in stark contrast to just 2.7% in the placebo group. These differences were statistically significant (P < 0.0001). Furthermore, the percentages of participants meeting various weight loss targets were striking: 87.3%, 97.2%, and 95.2% of those in the 5 mg, 10 mg, and 15 mg groups achieved a ≥5% reduction, while only 28.6% in the placebo group succeeded.

The ongoing weight loss observed throughout the study indicates that Olatorepatide has the potential to aid patients long-term. Additionally, this study also assessed several metabolic benefits from the medication, including improvements in blood pressure, cholesterol levels, and hemoglobin A1c markers – factors crucial for managing diabetes and metabolic disorders.

Regarding safety, the side effects experienced by participants were consistent with those seen in other incretin therapies. The incidence of gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation was notably lower than that of currently available treatments. The incidence rates of nausea and vomiting were recorded at 7.8% and 4.9%, respectively, with no participants withdrawing from the study due to adverse events related to Olatorepatide.

Olatorepatide’s mechanism revolves around its dual action on the GLP-1 and GIP receptor pathways, effectively addressing appetite regulation, glucose metabolism, and energy balance. This innovative approach reflects the compound’s potential to merge substantial weight loss efficacy with enhanced tolerability, setting it apart in the landscape of weight management solutions.

The importance of presenting these findings at EASD cannot be understated. This conference ranks among the top global summits dedicated to diabetes and metabolism research innovation. The selection of the Olatorepatide phase III study for a late-breaking oral presentation underscores the community's acknowledgment of the data's quality and clinical relevance.

Currently, Olatorepatide is also undergoing phase III clinical trials for the treatment of type 2 diabetes in China, following a strategic collaboration signed between Hansoh Pharma and Regeneron in June 2025. Registration applications for Olatorepatide Injection have already been submitted to China's National Medical Products Administration (NMPA), seeking approval for long-term weight management solutions.

In conclusion, the outcomes from the LIGHTEN trial illustrate the promising potential of Olatorepatide as a groundbreaking medication for individuals struggling with obesity and associated metabolic problems. As Hansoh Pharma continues to innovate with a mission of "Continuous Innovations for Better Life," the introduction of Olatorepatide could reshape weight management and diabetes treatment paradigms.